OBSIDIAN THERAPEUTICS, INC.
OBXLoading price...
Overview
Previous Close--
Open--
Ask--
Bid--
Day's Range -
52 Week Range -
PE Ratio(TTM)--
Market Cap--
Volume--
Avg. Volume--
12 Months Earnings-95.25M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 |
|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 99.34M | 105.67M | 91.25M |
| Profit after Tax (Net Income) | -95.25M | -100.61M | -83.11M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Cambridge, United States
Website: https://obsidiantx.com
Executive Chairman of the Board: Dr. Maria Fardis M.B.A., Ph.D.
Employees: 71
About Company:
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.